Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer by unknown
Suriano et al. Journal of Experimental & Clinical Cancer Research 2013, 32:87
http://www.jeccr.com/content/32/1/87RESEARCH Open AccessTumor associated macrophages polarization
dictates the efficacy of BCG instillation in non-
muscle invasive urothelial bladder cancer
Francesca Suriano1*, Daniele Santini2, Giuseppe Perrone3, Michela Amato3, Bruno Vincenzi2, Giuseppe Tonini2,
Andrea Onetti Muda3, Sara Boggia4, Maurizio Buscarini1 and Francesco Pantano2Abstract
Background: To evaluate the prognostic role of TAMs in patients affected by non-muscle invasive bladder cancer
(NMIBC), undergone Trans Urethral Resection of Bladder (TURB) and Bacillus Calmette-Guerin (BCG) therapy.
Methods: Data from 40 patients (36 men, 4 women), mean age 69 years (40-83 years), treated for NMIBC with
TURB and BCG instillation were collected. Two different groups were considered: group with and group without
bladder cancer recurrence. Correlations between immunofluorescence measured Mtot, M1 and M2 infiltration and
clinicopathological parameters were evaluated using Spearman and Mann–Whitney methods. The recurrence-free
survival rate was calculated using the Kaplan-Meier method.
Results: CD68 positive cells (Mtot) were observed in all specimens tested. High Mtot, M1 and M2 infiltration was
observed in patients with disease recurrence, even before endovescical BCG instillation. Significant value for M2
infiltration (p = 0,042) was found calculating significativity between two group medians before BCG therapy.
p = 0,072 and p = 0,180 were observed correlating median of Mtot and M1 between two groups of patients
respectively. Values of p = 0,44, p = 0,23 and p = 0,64 from correlation between DFS and Mtot, M1 and M2 median
in patients before endovescical BCG instillation, were calculated respectively. Comparing DFS and Mtot, M1 and M2
median in patients group after endovescical BCG instillation significant values were obtained (p = 0,020; p = 0,02;
and p = 0,029 respectively).
Conclusions: M2 tumor infiltration could be a prognostic value of recurrence in patients with NMIBC.
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PrognosisBackground
Urothelial bladder cancer is the second cancer for inci-
dence of urinary tract. In 2008, 90.900 new cases in
Europe (86.300 males and 4.600 females) have been re-
ported. Bladder cancer is responsible of 4.1% cancer-
correlated death in men and 1.8% in women [1].
75% of urothelial bladder cancer are non-muscle invasive
(NMIBC) at diagnosis [2]. Standard therapy for NMIBC in-
cludes trans-urethral resection of tumor, followed by endo-
vescical instillation of chemo- / immuno-therapy for high* Correspondence: fracbm@yahoo.it
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reproduction in any medium, provided the orgrade disease [3-5]. Mycobacterium bovis (Bacillus Calmette
Guerin–BCG) has been established as the most effective
adjuvant treatment for decreasing recurrence and tumor
progression risk. Since its first use in 1976 [6] major efforts
have been directed to understand the mechanism of BCG
mediating anti-bladder cancer immunity. Despite its clinical
benefit the mechanism underlying the antitumor activity of
intravescical BCG instillation has not been clarified. How-
ever, it has been reported that intravescical BCG provokes
an inflammation involving the contribution of various im-
mune cells including cells associated with the innate im-
mune response. Data from Ayari et al suggested that
patients with high level of infiltration by TAMs in the can-
cer area don’t respond as well to BCG immunotherapy [7].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 CD68/CD163 expression in M2 macrophage in bladder cancer. A) CD68 (green), shows nucleated cells positive staining for CD68;
B) CD163 (red 2), shows CD163 staining in macrophage phenotype; C) DAPI, shows the cell nuclei marked with DAPI; D) merged image of DAPI,
CD68 and CD163 showing a number of macrophages with positive staining for the phenotype marker M2. Original magnification × 400.
Figure 2 CD68/iNOS expression in M1 macrophage in bladder cancer. A) CD68 (green), shows nucleated cells positive staining for CD68;
B) iNOS (red), shows iNOS staining in macrophage phenotype 1; C) DAPI, shows the cell nuclei marked with DAPI; D) merged image of DAPI,
CD68 and iNOS showing a number of macrophages with positive staining for the phenotype marker M1. Original magnification × 400.
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Table 1 Patients without recurrence
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Table 2 Patients with recurrence
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http://www.jeccr.com/content/32/1/87Tumor-associated macrophages (TAMs) represent a
substantial fraction of the growing tumor mass and are
associated with poor prognosis in several human cancers
[8]. TAMs exist in two different polarizations state clas-
sified as M1 and M2. M1 macrophages show a protect-
ive role in tumor-genesis activating tumor-killing
mechanisms and antagonizing the activities of M2.
M2 macrophages are clearly involved in suppression of
adaptive tumour-specific immune responses and in pro-
motion of tumour growth, invasion, stroma remodelling
and angiogenesis [9-13].
Considering the rationale of BCG use, we hypothe-
sized that endovescical instillation efficacy could be
modulated according to TAM polarization and con-
versely macrophage could be influenced by BCG itself.
Material and methods
A total of 40 patients (36 males and 4 females), mean age
69 years (40-83 years), diagnosed with non-muscle invasive
bladder cancer (NMIBC) at our institution (Campus Bio-
Medico, University of Rome) from 1999 to 2011 were se-
lected randomly for study. Between them, 23 patients had
not recurrence at follow-up versus 17 patients with bladder
cancer recurrence.
Diagnosis of bladder cancer was made by histological
examination of specimens obtained by transurethral blad-
der biopsy. Histological specimens were fixed in 10% neu-
tral buffered formalin and routinely processed for paraffin
embedding. Serial 5 μm sections were cut, stained with
hematoxylin and reviewed by a pathologist.
All patients underwent same intravescical BCG regimens
(80 mg Immucyst/80 ml Salin solution 0.9%). After initial
therapy, patients were followed with periodic cystoscopy,
urine cytology and Uro-TC.
We evaluated two consecutive histological sections (be-
fore and after intravescical BCG instillations) by Immuno-
florescence. Histologic reviewers were blinded to
recurrence outcomes. TAMs were labeled using CD68
monoclonal antibody (monoclonal mouse clone PG-M1),
Ab anti-iNOS (Rabbit mAb) and Ab anti-CD163 (Rabbit
mAb; 1:200). DAPI was used for detection of nucleate cells.
Cells positive for CD68 were considered whole macrophage
population (Mtot); cells positive for CD68 and CD163 were
considered M2 population and those positive for CD68 and
iNOS were considered M1 population (Figures 1 and 2).
For systematic counting 5 high power fields were
chosen randomly under a microscope (Eclipse 80i Nikon
microscope, Tokyo, Japan) at 400× magnification.
In order to assess whether there is any value of the
macrophage density of M1 and M2 in predicting prognosis,
the median value of the macrophage density of two popula-
tions was used as a cut-off point to dichotomize the 40 pa-
tients into a group with a macrophage density above or
below the median value.Statistical analysis was performed using SPSS software
(vers. 17). Correlations between immunofluorescence
measured Mtot, M1 and M2 infiltration and clinical-
pathological parameters were evaluate using Spearman and
Mann–Whitney methods. The recurrence-free survival rate
was calculated using the Kaplan-Meier method.
Results
CD68 positive cells (Mtot) were observed in all speci-
mens tested. Considering two patient populations (re-
currence and no-recurrence groups) we found a
different M1 and M2 infiltration (Tables 1 and 2). We
observed a higher Mtot, M1 and M2 infiltration in pa-
tients with disease recurrence, even before endovescical
BCG instillation. Calculating significativity between two
groups median before BCG therapy, we found a signifi-
cant value for M2 infiltration (p = 0,042) (Figure 3). In-
stead, there were not significant values correlating
median of Mtot and M1 between two groups of patients
(p = 0,072 and p = 0,180 respectively) (Figures 4 and 5).
Correlating disease-free survival (DFS) and Mtot, M1 and
M2 median in patients before endovescical BCG instilla-
tion, we didn’t observe significant values. p = 0,44 from cor-
relation between DFS and Mtot median, p = 0,23 from
correlation between DFS and M1 median, p = 0,64 from
correlation between DFS and M2 median were calculated.
On the contrary, significant values comparing DFS and
Mtot, M1 and M2 median in patients group after endoves-
cical BCG instillation (p = 0,020; p = 0,02; and p = 0,029 re-
spectively) were present (Figures 6, 7 and 8).
Discussion
Bladder cancer is one of the most widespread cancers
afflicting men and women, and its incidence grows expo-
nentially each year. Early studies reported that the macro-
phages increase in bladder cancer is associated with high
survival and invasive capacity [14]. Activated macrophages
promote tumor-genesis through the expression of growth
Figure 3 Correlation between M2 median of two groups of patients (recurrence and no recurrence).
Suriano et al. Journal of Experimental & Clinical Cancer Research 2013, 32:87 Page 4 of 7
http://www.jeccr.com/content/32/1/87factors and matrix proteases, promotion of angiogenesis
and suppression of anti-tumoral immune response [14,15].
As Dufresne et al described in their study [16], pro-
inflammatory M1 should suppress tumor growth; instead
anti-inflammatory M2, via production of IL-10 and other
soluble factors, suppress the anti-tumoral effects of M1.
In many human neoplasms, including lung, breast, cervix,
ovary and pancreas cancers, the presence of extensive TAM
infiltrate correlates with poor prognosis. In other tumors,
including brain and prostate cancer, there is conflictingFigure 4 Correlation between Mtot median of two groups of patientsevidence regarding the role of macrophages in survival out-
comes [17-21]. The basis for these conflicting data may be
explained considering that in these studies tumor-
associated macrophages were detected only by the immu-
nohistochemical analysis of CD68+ cells. In fact both M1
and M2 phenotypes share the expression for CD68, there-
fore the use of CD68 alone might not represent a reliable
marker in evaluating the real impact of the two subtypes.
The role of TAM in non-muscle invasive bladder can-
cer was previously investigated by Ayary et al finding a(recurrence and no recurrence).
Figure 5 Correlation between M1 median of two groups of patients (recurrence and no recurrence).
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Anyway this work did not take into account the real role
of the two opposite macrophage population.
In our study we used double-staining for CD68/NOS2 as
markers for M1 macrophages and CD68/CD163 as markers
for M2 macrophages to be in accordance with the most
part of previously published studies that performed a
phenotypic characterization of macrophages polarization
[17,20-27].Figure 6 DFS and Mtot median in patients underwent
BCG instillation.The haemoglobin scavenger receptor, CD 163, is
expressed almost exclusively on macrophages and
monocytes, and it is strongly upregulated by anti-
inflammatory cytokines, important for M2 polarization.
Conversely, macrophages M1 polarized by exposure to
interferon (IFN)-γ or LPS up-regulate inducible nitric
oxide synthase (iNOS) to convert into nitric oxide (NO)
that combining with oxygen radicals leads to the forma-
tion of cytotoxic peroxynitrite. These markers are notFigure 7 DFS and M1 median in patients underwent
BCG instillation.
Figure 8 DFS and M2 median in patients underwent
BCG instillation.
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http://www.jeccr.com/content/32/1/87absolutely specific, for example CD68 has been found in
immature CD1a-positive dendritic cells.
CD163 is also expressed in some dendritic cells, and
iNOS is expressed by endothelial cells as well as by arterial
wall smooth muscle cells. For these reasons we have given
particular attention to cell morphology in order to
minimize potential bias [20-23,28-31].Conclusion
In this study we investigated the role of tumor-infiltrating
macrophages in non-muscle invasive bladder cancer. In
particular, we obtained more insight in clinical significance
of macrophage polarization in predicting recurrence after
BCG instillation. Our findings support the idea that a sus-
tained M2 infiltration in tumor microenvironment could
significantly limit the efficacy of BCG suggesting the need
of a well planned therapeutical strategy in non-muscle inva-
sive bladder cancer patients.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
FS and FP were the main authors of the manuscript; SB and FP collected
and studied the bibliography; DS, MB, GT, AOM and BV participated in the
sequence alignment and drafted the manuscript; FS corrected the language
form; MA and GP carried out immunohistochemical studies; FS drafted the
article and revised it critically for important intellectual content. All authors
read and approved the final manuscript.
Author details
1Department of Urology, Campus Bio-Medico, University of Rome,
Via Spilimbergo 10, int 35, 00182 Rome, Italy. 2Department of Oncology,
Campus Bio-Medico, University of Rome, Via Alvaro del Portillo 200, 00128
Rome, Italy. 3Department of Anatomical Pathology, Campus Bio-Medico,University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
4Sant’Andrea Hospital, Rome, Italy.
Received: 21 August 2013 Accepted: 28 October 2013
Published: 5 November 2013References
1. Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence
and mortality in Europe in 2008. Eur J Cancer 2010, 46:765–781.
2. Fleming JD, Cooper JS, Jenson DE, et al: AJCC cancer staging manual. 5th
edition; 1997.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al: Predicting recurrence
and progression in individual patients with stage TaT1 bladder cancer
using EORTC risk tables:a combined analysis of 2596 patients from
seven EORTC trials. Eur Urol 2006, 49(3):465–466.
4. Duque JLF, Loughlin KR: An overview of the treatment of superficial
bladder cancer. Urol Clin North AM 2000, 1:125–135.
5. Chade DC, Borra RC, Nascimento IP, Andrade PM, et al: Immunomodulatory
effects of recombinant BCG ex pressing pertossi toxin on TNF-alfa and
IL-10 in a bladder cancer model. J Exp Clin Cancer Res 2008, 27:78.
6. Morales A, Eidinger D, Bruce AW: Intracavitary bacillus calmette guerin in
the treatment of superficial bladder tumors. J Urol 1976, 2:180–183.
7. Ayary C, LaRue H, Hovington H, Decobert M, Fradet Y, et al: Bladder tumor
infiltrating mature dendritic cells and macrophages as predictors of
response to bacillus calmette guerin immunotherapy. Eur Urol 2009,
55(6):1386–1396.
8. Bingle L, Brown NJ, Lewis CE: The role of tumor associated macrophages
in tumor progression: implications for new anticarncer terapie. J Pathol
2002, 196(3):254–265.
9. Andreu P, et al: FcRy activation regulates inflammation-associated squa-
mous carcinogenesis. Cancer Cell 2010, 17:121–134.
10. De Visser KE, Korets LV, Coussens LM: De novo carcinogenesis promoted
by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005,
7:411–423.
11. Nardin A, Abastado JP: Macrophages and cancer. Front Biosci 2008,
13:3494–3505.
12. Yang XD, et al: Histamine deficiency promotes inflammation-associated
carcinogenesis through reduced myeloid maturation and accumulation
of CD11b + Ly6G + immature myeloid cells. Nature Med 2011, 17:87–95.
13. Sierra JR, et al: Tumor angiogenesis and progression are enhanced by
Sema4D produced by tumor-associated macrophages. J Exp Med 2008,
205:1673–1685.
14. Hanada T, Nakagawa M, Emoto A, et al: Prognostic value of tumor-
associated macrophage count in human bladder cancer. Int J Urol 2000,
7:263–269.
15. Wei F, Wang H, Huang Q, et al: Pharmacokinetics of combined gene
therapy expressing constitutive human GM-CSF and hyperthermia-
regulated human IL-12. J Exp Clin Cancer Res 2013, 32:5.
16. Dufresne M, Dumas G, Asselin E, et al: Pro-inflammatory type-1 and anti-
inflammatory type-2 macrophages differentially modulate cell survival
and invasion of human bladder carcinoma. Mol Immunol 2008,
48:1556–1567.
17. Song L, Asgharzadeh S, Salo J, et al: Valpha24-invariant NKT cells mediate
antitumor activity via killing of tumor-associated macrophages.
J Clin Invest 2009, 119(6):1524–1536.
18. Jensen TO, Schmidt H, Moller HJ, et al: Macrophage markers in serum and
tumor have prognostic impact in American Joint Committee on Cancer
stage I/II melanoma. J Clin Oncol 2009, 27(20):3330–3337.
19. Kurahara H, Shinchi H, Mataki Y, et al: Significance of M2-polarized tumor-
associated macrophage in pancreatic cancer. J Surg Res 2011,
167(2):e211–e219.
20. Welsh TJ, Green RH, Richardson D, et al: Macrophage and mast-cell inva-
sion of tumor cell islets confers a marked survival advantage in non-
small cell lung cancer. J Clin Oncol 2005, 23(35):8959–8967.
21. Wang R, Lu M, Zhang J, Chen H, et al: Increased IL-10 mRNA expression in
tumor associated macrophage correlated with late stage of lung cancer.
J Exp Clin Cancer Res 2011, 30:62.
22. Puhakka A, Kinnula V, Napankangas U, et al: High expression of nitric oxide
synthases is a favorable prognostic sign in non-small cell lung carcin-
oma. APMIS 2003, 111(12):1137–1146.
Suriano et al. Journal of Experimental & Clinical Cancer Research 2013, 32:87 Page 7 of 7
http://www.jeccr.com/content/32/1/8723. Tran TA, Kallakury BV, Ambros RA, et al: Prognostic significante of tumor
necrosis factors and their receptors in nonsmall cell lung carcinoma.
Cancer 1998, 83(2):276–282.
24. Binion DG, Fu S, Ramanujam KS, et al: iNOS expression in human intestinal
microvascular endothelial cells inhibits leukocyte adhesion. Am J Physiol
1998, 275(3 Pt 1):G592–G603.
25. Luoma JS, Stralin P, Marklund SL, et al: Expression of extracellular SOD and
iNOS in macrophages and smooth muscle cells in human and rabbit
atherosclerotic lesions: colocalization with epitome characteristics of
oxidized LDL and peroxynitrite-modified proteins. Arterioscler Thromb Vasc
Biol 1998, 18(2):157–167.
26. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy
versus surgery alone for resectable gastroesophageal cancer.
N Engl J Med 2006, 355(1):11–20.
27. Cuschieri A, Fayers P, Fielding J, The Surgical Cooperative Group, et al:
Postoperative morbidity and mortality after D1 and D2 resections for
gastric cancer: preliminary results of the MRC randomized controlled
surgical trial. Lancet 1996, 347(9007):995–999.
28. Ohno S, Inagawa H, Dhar DK, et al: Role of tumor-associated macrophages
(TAM) in advanced gastric carcinoma: the Impact on FasL-mediated
counterattack. Anticancer Res 2005, 25(1B):463–470.
29. Moestrup SK, Moller HJ: CD163: a regulated hemoglobin scavenger
receptor with a role in the anti-inflammatory response. Ann Med 2004,
36:347–354.
30. Stout RD, Jiang C, Matta B, et al: Macrophages sequentially change their
functional phenotype in response to changes in microenvironmental
influences. J Immunol 2005, 175:342–349.
31. Foukas PG, Tsilivakos V, Zacharatos P, et al: Expression of HLA-DR is re-
duced in tumor infiltrating immune cells (TIICs) and regional lymph
nodes of non-small cell lung carcinomas: a putative mechanism of
tumor-induced immunosuppression? Anticancer Res 2001,
21(4A):2609–2615.
doi:10.1186/1756-9966-32-87
Cite this article as: Suriano et al.: Tumor associated macrophages
polarization dictates the efficacy of BCG instillation in non-muscle inva-
sive urothelial bladder cancer. Journal of Experimental & Clinical Cancer Re-
search 2013 32:87.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
